Janney Montgomery Scott LLC Boosts Stake in Zimmer Biomet Holdings, Inc. $ZBH

Janney Montgomery Scott LLC lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 22.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,267 shares of the medical equipment provider’s stock after buying an additional 7,992 shares during the period. Janney Montgomery Scott LLC’s holdings in Zimmer Biomet were worth $4,003,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. DV Equities LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $25,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet during the 4th quarter valued at about $30,000. Gen Wealth Partners Inc bought a new position in Zimmer Biomet in the fourth quarter worth approximately $31,000. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet during the fourth quarter valued at about $32,000. Finally, Grove Bank & Trust raised its stake in shares of Zimmer Biomet by 431.6% during the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 328 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ZBH shares. Wells Fargo & Company cut their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 29th. Truist Financial reissued a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday. Stifel Nicolaus decreased their target price on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Finally, Leerink Partners initiated coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They issued a “hold” rating and a $101.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $102.70.

Insiders Place Their Bets

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.28% of the stock is currently owned by company insiders.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded up $1.33 during mid-day trading on Tuesday, hitting $91.09. 221,603 shares of the company were exchanged, compared to its average volume of 2,296,240. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The business’s 50 day simple moving average is $86.09 and its two-hundred day simple moving average is $89.79. The company has a market capitalization of $17.62 billion, a P/E ratio of 23.64, a PEG ratio of 2.58 and a beta of 0.46.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the previous year, the business posted $1.81 earnings per share. The company’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is currently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.